Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
18 janv. 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...